UK Cancer Diagnostics Market 2014: Sales Forecasts, Supplier Shares, Competitive Strategies

January 2014 | 620 pages | ID: 27058962D50EN
Venture Planning Group

Abstracts

Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350.

Summary

This comprehensive report contains 620 pages, 85 tables, and presents analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the UK cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the UK cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Cancer Diagnostic Tests

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

• Sales and market shares of major suppliers, by individual cancer diagnostic test.
• Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:
  • Hospitals
  • Commercial/Private Laboratories
• Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.
• Cancer statistics, etiology and recent developments.

Current and Emerging Products

• Review of over 200 current and emerging cancer diagnostic tests, including:
  • Biochemical Markers
  • Oncogenes
  • Growth Factors
  • Hormones
  • Colony Stimulating Factors
  • Lymphokines
  • Immunohistochemical Stains, and others.
• Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

• Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
• Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Contains 620 pages and 85 tables

Contents

I. INTRODUCTION

II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
  1. Breast Cancer
  2. Lung Cancer
  3. Colon and Rectum Cancer
  4. Prostate Cancer
  5. Stomach Cancer
  6. Leukemia
  7. Lymphoma
  8. Oral Cancer
  9. Skin Cancer
  10. Uterine Cancer
  11. Ovarian Cancer
  12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
  1. Introduction
  2. Tumor Marker Classification
  3. ACTH
  4. Alpha-Fetoprotein (AFP)
  5. Beta-2 Microglobulin
  6. CA 15-3/27.29
  7. CA 19-9
  8. CA-125
  9. Calcitonin
  10. Carcinoembrionic Antigen (CEA)
  11. Estrogen and Progesterone Receptors
  12. Ferritin
  13. Gastrin
  14. Human Chorionic Gonadotropin (HCG)
  15. Insulin
  16. NSE
  17. Occult Blood
  18. PAP Smear/HPV
  19. Prostatic Acid Phosphatase (PAP)
  20. Prostate-Specific Antigen (PSA)
  21. Squamous Cell Carcinoma Antigen (SCC)
  22. T and B Lymphocytes
  23. TdT
  24. Thyroglobulin
  25. Tissue Polypeptide Antigen (TPA)
  26. Biochemical Tumor Markers
    ADA
    - B-Protein
    PNP
    5'-Nucleotidase
  27. Oncogenes
    Abl/abl-bcr
    AIB1
    - BCL-2
    - BRCA1
    - CD44
    C-fos
    C-myb
    C-myc
    CYP-17
    Erb-B
    HPC1
    N-myc
    P40
    P51
    P53
    PIK3CA
    PTI-1
    Ras
    Reg
    Sis
    Src
  28. Polypeptide Growth Factors
    Basic Fibroblast Growth Factor
    Beta-TGF
    - Cachectin (TNT)
    - Calmodulin
    - ECFR
    - Nerve Growth Factor (NGF)
    - Epidermal Growth Factor (EGF)
    - Ornithine Decarboxylase
    - Transferrin
    - Transforming Growth Factor-Alpha
  29. Ectopic Hormones
  30. Colony Stimulating Factors
  31. Lymphokines
    - Alpha-Interferon
    - B Cell Growth Factors
    - B Cell Growth Factor (BCGF)
    - Gamma-Interferon
    - Interleukin-1 (IL-1)
    - Macrophage Activating Factor
  32. Immunohistochemical Stains
  33. Emerging Tumor Markers
    - N-Acetylglucosamine
    - Actin
    - Alpha-Actin
    - Antineuronal Antibodies
    - 7B2
    - B72.3
    - Bax
    - BCD-F9
    - BLCA-4
    - Blood Group Antigens A,B,H
    - CA
    - CA 72-4/TAG-72
    - CA
    - CA-242
    - CA-549
    - CAM
    - CAR-3
    - Cathepsin-D
    - Chromogranin A and B
    - Cluster 1 Antigen
    - Cluster-5/5A Antigen
    - CTA
    - CU18
    - DR-70
    - DU-PAN-2
    - Endometrial Bleeding Associated Factor
    - Endostatin
    - Epithelial Membrane Antigen
    - Feulgen Hydrolysis
    - Fibronectin
    - FSH
    - (1->3)-L-fucosyltransferase
    - Gastrin-Releasing Peptide (GRP)
    - GDCFP-15
    - Glucagon
    - Glycoamines
    - H23
    - Her-2
    - Human Carcinoma Antigen
    - HPA
    - HSP27
    - Intermediate Filaments
    - Cytokeratins/CK18/Cyfra 21-1
    - Desmin
    - Gliofibrillary Acid Protein
    - Neurofilaments
    - Vimentin
    - KA
    - Kinases
    - KP16D3
    - LAI
    - Leukocyte Common Antigen
    - Lewis Antigens
    - Lysophosphatidic Acid (LPA)
    - Ma 695/Ma
    - MABDF3
    - MAG
    - ME1
    - Minactivin
    - MN/CA9
    - MSA
    - Mucin Cancer Antigen (MCA)
    - Multiple Tumor Suppressor
    - Myosin
    - NEA-130
    - NMP22
    - OA-519
    - Opiod Peptides
    - P-glycoprotein
    - Pancreatic Oncofetal Antigen (POA)
    - Placental Lactogen
    - PR92
    - Proliferative Index, Ki-67
    - Px
    - RB Inactivation/Deletion
    - Ret
    - SCCL
    - Selectin
    - Sialic Acid
    - Sialyl SSEA-1/SLX
    - SN10
    - Somatostatin
    - TA-90
    - TABA
    - Tachykinin
    - TAG
    - TPS
    - Troponin
    - Tubulin
    - VCAM
    - VEGF
    - Villen
C. Instrumentation Review And Market Needs
D. Current and Emerging Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
    a. Technological Principle
    b. Radioimmunoassay (RIA)
     c. Enzyme Immunoassays (EIA)
      - Overview
      - ELISA
      - Immunofiltration
      - Particle-Membrane Capture Immunoassay
      - Enzyme Amplification
    d. Fluorescent Immunoassays
    e. Luminescence
      - Chemiluminescence
      - Bioluminescence
    f. Latex Agglutination
    g. Immunoprecipitation
    h. Affinity Chromatographu
    e. Liposome Flow-Injection Immunoassay
  3. Molecular Diagnostics
    a. Technology Overview
    b. Amplification Methods
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
     c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas       Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
    a. CT
    b. MRI
     c. NMR
    d. PET
    e. Photonics Spectroscopy
G. Personal Testing

III. U.K.

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers Sales and Market Shares

X. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

XI. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XII. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
  1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation Factor

XIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

XIV. COMPETITIVE PROFILES

Abbott
AdnaGen
Agilent Technologies
Applied Gene Technologies
Arca/Nuvelo
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio/Innogenetics
Guided Therapeutics
Hologic/Gen-Probe
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen/Ipsogen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

XV. APPENDIXES:

Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications
Appendix II: Assumed Currency Exchange Rates

List Of Tables

LIST OF TABLES

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Executive Summary Table: U.K., Total Tumor Marker Test Volume and Sales Forecast by Market Segment
U.K., Estimated Cancer Death Rates Per 100,000 Population
U.K., Laboratories Performing Tumor Marker Tests by Market Segment
U.K., Hospital Laboratories Performing Tumor Marker Tests by Bed Size
U.K., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume
U.K., Total Tumor Marker Testing Volume Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Test Volume Forecast
U.K., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
U.K., Total Tumor Marker Sales Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Sales Forecast by Test
U.K., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
U.K., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CEA Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Colon-Specific Antigen Test Volume And Diagnostics Sales by Market Segment
U.K., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Total Tumor Marker Sales and Market Shares Forecast
U.K., CEA Testing Market Diagnostics Sales by Major Supplier
U.K., PSA Testing Market Diagnostics Sales by Major Supplier